LMRI
Lumexa Imaging Holdings, Inc. Common Stock
LMRI lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
LMRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
LMRI's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
LMRI PE Valuation
LMRI has no meaningful PE right now: it lost money over the past year.
LMRI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for LMRI, with profitability improving.
LMRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.80 | — |
| Q3 2026 | -$0.26 | +$0.20 |
LMRI lost $0.26 per share over the past year, a smaller loss than the year before.
LMRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $272M | +5% |
| Q2 2026 | $264.2M | +5.1% |
| Q1 2026 | $252.5M | +3.1% |
| Q4 2025 | $267.7M | +7.9% |
LMRI's revenue has grown year over year every quarter since late 2025: $272M last quarter, up 5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +5.3 points |
| Q2 2026 | 8.7% | +4.3 points |
| Q1 2026 | 7.7% | +3.6 points |
| Q4 2025 | -2.8% | -8.9 points |
| Q3 2025 | 5% | N/A |
| Q2 2025 | 4.4% | N/A |
| Q1 2025 | 4.1% | N/A |
| Q4 2024 | 6.2% | N/A |
LMRI's operating margin was 10% last quarter, up 5.3 points from the same quarter a year ago.
LMRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20.6M | +$22.4M |
| Q2 2026 | $23.1M | +$25.7M |
| Q1 2026 | -$2.4M | +$12.6M |
| Q4 2025 | $12.9M | -34% |
LMRI generated $54M in free cash flow over the past year, more than ten times what it generated the year before.
LMRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +217K shares |
| 1 year | +16% | +13.5M shares |
LMRI has 96M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
LMRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.2x | High |
| Q2 2026 | 6.1x | High |
| Q1 2026 | 5.9x | High |
| Q4 2025 | 6.4x | High |
| Q3 2025 | 8.7x | High |
LMRI's net debt is about 6.2 years of its operating earnings (EBITDA), down from 8.7 years a year ago.
LMRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.7 | Neutral |
| Stochastic | 70.8 | Neutral |
LMRI's weekly RSI is 64 (neutral) and its Stochastic is 71 (neutral).
LMRI PE vs Healthcare Sector
LMRI has no meaningful PE right now: it lost money over the past year.
LMRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.7 | 28% above |
| 20 week MA | $11.6 | 29% above |
LMRI is in an uptrend: it's above all two of its weekly moving averages, and 29% above its 20-week average.
LMRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $18.5 | $18.0 | -2.9% |
| 2026 YTD | $18.0 | $14.9 | -17% |
LMRI has finished every year since 2025 lower, and it's down 17% so far in 2026.